CAJ | 학술논문

目的观察保肾康联合依那普利治疗糖尿病肾病的疗效.方法将54例2型糖尿病肾病患者,随机分为对照组和治疗组各27例,对照组予依那普利等常规治疗,治疗组在常规治疗的基础上加用保肾康,两组连续用药12周,观察各项指标并分析.结果两组治疗前后24h尿蛋白排泄率、血肌酐及三酰甘油有明显改善(P<0.01),糖化血红蛋白、平均动脉血压也有不同程度的改善(P<0.05),且治疗组优于对照组(P<0.05).结论保肾康联合依那普利治疗糖尿病肾病疗效显著,且无明显不良反应,值得临床推广应用.
목적관찰보신강연합의나보리치료당뇨병신병적료효.방법장54례2형당뇨병신병환자,수궤분위대조조화치료조각27례,대조조여의나보리등상규치료,치료조재상규치료적기출상가용보신강,량조련속용약12주,관찰각항지표병분석.결과량조치료전후24h뇨단백배설솔、혈기항급삼선감유유명현개선(P<0.01),당화혈홍단백、평균동맥혈압야유불동정도적개선(P<0.05),차치료조우우대조조(P<0.05).결론보신강연합의나보리치료당뇨병신병료효현저,차무명현불량반응,치득림상추엄응용.
Objective To observe curative effect of ferulaic acid piperazine combined with Enalapril in diabetic nephropathy. Methods The 54 cases 2 diabetic were randomly divided into two groups. The treatment group of 27 cases was treated with conventional therapy and ferulaic acid piperazine, the control group of 27 cases was treated with conventional therapy only. The two groups applied drugs continuously for 12 weeks, and then observed the index and analysis on. Results The urinary albumin excretion rate in 24 hours and Scr were significantly lower than that of prior treatment (P<0.01) and there were significant difference in HbA1c and TG and MAP between pre and post treatment in two groups (P<0.05). The data of combined treatment group were better than those of the control group (P<0.05). Conclusion The combined treatment of ferulaic acid piperazine and Enalapril is effective in diabetic nephropathy, and which has no observed adverse effect. It is deserved to been clinically spread and applied.